Heterologous COVID-19 Vaccination; Sinopharm and Pfizer-BioNTech
DOI:
https://doi.org/10.22317/imj.v5i4.1146Keywords:
COVID-19, COVID-19 Vaccine, Mixing Vaccines, Pfizer-BioNTech, Sinopaharm, Heterologous VaccinationAbstract
This short communication and highlights is the first one talking about receiving two different Anti-COVID-19 vaccines in full doses. In a small group of almost medical personals in Duhok city, Kurdistan region of Iraq, for the first time in the world 15 doctors who were vaccinated with two doses of Sinopharm at early March were revaccinated with two doses of Pfizer-BioNTech after approximately 5-6 months. They were developed a good immune response without serious side effects so far. This will direct us toward potential safety protocol of mixing full doses of different vaccines at least in the short term. No serious side effects in the short term had been registered in this new combination. Such policy might open ways for further larger studies for taking different Anti-COVID-19 vaccines in full doses.
References
1. World Health Organization. Coronavirus disease (COVID-19): Vaccines [Internet]. (2020). Available from: https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines?adgroupsurvey={adgroupsurvey}&gclid=EAIaIQobChMI4v6d2pjN8gIVDdd3Ch0a2AwKEAAYASAAEgI-T_D_BwE.
2. World Health Organization. Coronavirus disease (COVID-19): Vaccines [Internet]. (2020). Available from: https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines?adgroupsurvey={adgroupsurvey}&gclid=EAIaIQobChMI4v6d2pjN8gIVDdd3Ch0a2AwKEAAYASAAEgI-T_D_BwE.
3. Hillus, D., Schwarz, T., Tober-Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., Jentzsch, S., Helbig, E. T., Lippert, L. J., Tscheak, P., Schmidt, M. L., Riege, J., Solarek, A., von Kalle, C., Dang-Heine, C., Gruell, H., Kopankiewicz, P., Suttorp, N., Drosten, C., Bias, H., … Sander, L. E. (2021). Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. The Lancet. Respiratory medicine, S2213-2600(21)00357-X. Advance online publication. https://doi.org/10.1016/S2213-2600(21)00357-X.
4. Shaw, R. H., Stuart, A., Greenland, M., Liu, X., Nguyen Van-Tam, J. S., Snape, M. D., & Com-COV Study Group (2021). Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet (London, England), 397(10289), 2043–2046. https://doi.org/10.1016/S0140-6736(21)01115-6.
5. Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, GarcÃa-Pérez J, Campins M, Portolés A, González-Pérez M, GarcÃa Morales MT, Arana-Arri E, Aldea M, DÃez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustà A, Pérez-Ingidua C, Gómez de la Cámara A, Arribas JR, Ochando J, Alcamà J, Belda-Iniesta C, FrÃas J; CombiVacS Study Group. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021 Jul 10;398(10295):121-130. doi: 10.1016/S0140-6736(21)01420-3. Epub 2021 Jun 25. Erratum in: Lancet. 2021 Aug 14;398(10300):582. PMID: 34181880; PMCID: PMC8233007.
6. Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Bernhardt G, Münch J, Hoffmann M, Pöhlmann S, Krey T, Bošnjak B, Förster R, Behrens GMN. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021 Jul 14. doi: 10.1038/s41591-021-01449-9. Epub ahead of print. PMID: 34262158.
7. Since Media Center. Expert reaction to preprint on immune response to mixed dose scheduling of COVID vaccines from the Com-COV study [Internet]. 2021 June 28th. Accessed on August 28th, 2021. Available from: expert reaction to preprint on immune response to mixed dose scheduling of COVID vaccines from the Com-COV study | Science Media Centre.
8. Makszimov V,. Tests show lack of antibodies for those vaccinated with China’s jab (2021) [Internet]. EURACTIV.com with Telex. Accessed on August 27th, 2021. Available from: https://www.euractiv.com/section/politics/short_news/tests-show-lack-of-antibodies-for-those-vaccinated-with-chinas-jab/.
9. Ferenci T, Sarkadi B. Virus neutralizing antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine. medRxiv. 2021 July 29. doi: https://doi.org/10.1101/2021.07.15.21260362.
10. Fermin M,. Ban on travelers vaccinated with Sinovac, Sinopharm probed (May 25th, 2021) [Internet]. Accessed on August 27th, 2021. Available from: Ban on travelers vaccinated with Sinovac, Sinopharm probed | Philippines Lifestyle News.
11. Mahase E. Covid-19: Moderna and Novavax vaccines to be tested in mixing vaccines trial BMJ 2021; 373 :n971 doi:10.1136/bmj.n971.
12. Callaway E. Mix-and-match COVID vaccines trigger potent immune response [Internet]. Nature. 2021 May 19th. Accessed on August 27th, 2021. Available from: Mix-and-match COVID vaccines trigger potent immune response (nature.com).
13. Duarte-Salles, T., & Prieto-Alhambra, D. (2021). Heterologous vaccine regimens against COVID-19. Lancet (London, England), 398(10295), 94–95. https://doi.org/10.1016/S0140-6736(21)01442-2.
14. Deming, M.E., Lyke, K.E. A ‘mix and match’ approach to SARS-CoV-2 vaccination. Nat Med (2021). https://doi.org/10.1038/s41591-021-01463-x.
15. Liu, X., Shaw, R. H., Stuart, A., Greenland, M., Aley, P. K., Andrews, N. J., Cameron, J. C., Charlton, S., Clutterbuck, E. A., Collins, A. M., Dinesh, T., England, A., Faust, S. N., Ferreira, D. M., Finn, A., Green, C. A., Hallis, B., Heath, P. T., Hill, H., Lambe, T., … Com-COV Study Group (2021). Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet (London, England), S0140-6736(21)01694-9. Advance online publication. https://doi.org/10.1016/S0140-6736(21)01694-9.
16. Behrens, G. M., Cossmann, A., Stankov, M. V., Nehlmeier, I., Kempf, A., Hoffmann, M., & Pöhlmann, S. (2021). SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination. Lancet (London, England), S0140-6736(21)01891-2. Advance online publication. https://doi.org/10.1016/S0140-6736(21)01891-2.
17. Mohammad, Ameen M. MD The pandemic of coronavirus: misconceptions from the land of Mesopotamia, International Journal of Surgery: Global Health: May 2021 - Volume 4 - Issue 3 - p e52. doi: 10.1097/GH9.0000000000000052
2. World Health Organization. Coronavirus disease (COVID-19): Vaccines [Internet]. (2020). Available from: https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines?adgroupsurvey={adgroupsurvey}&gclid=EAIaIQobChMI4v6d2pjN8gIVDdd3Ch0a2AwKEAAYASAAEgI-T_D_BwE.
3. Hillus, D., Schwarz, T., Tober-Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., Jentzsch, S., Helbig, E. T., Lippert, L. J., Tscheak, P., Schmidt, M. L., Riege, J., Solarek, A., von Kalle, C., Dang-Heine, C., Gruell, H., Kopankiewicz, P., Suttorp, N., Drosten, C., Bias, H., … Sander, L. E. (2021). Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. The Lancet. Respiratory medicine, S2213-2600(21)00357-X. Advance online publication. https://doi.org/10.1016/S2213-2600(21)00357-X.
4. Shaw, R. H., Stuart, A., Greenland, M., Liu, X., Nguyen Van-Tam, J. S., Snape, M. D., & Com-COV Study Group (2021). Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet (London, England), 397(10289), 2043–2046. https://doi.org/10.1016/S0140-6736(21)01115-6.
5. Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, GarcÃa-Pérez J, Campins M, Portolés A, González-Pérez M, GarcÃa Morales MT, Arana-Arri E, Aldea M, DÃez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustà A, Pérez-Ingidua C, Gómez de la Cámara A, Arribas JR, Ochando J, Alcamà J, Belda-Iniesta C, FrÃas J; CombiVacS Study Group. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021 Jul 10;398(10295):121-130. doi: 10.1016/S0140-6736(21)01420-3. Epub 2021 Jun 25. Erratum in: Lancet. 2021 Aug 14;398(10300):582. PMID: 34181880; PMCID: PMC8233007.
6. Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Bernhardt G, Münch J, Hoffmann M, Pöhlmann S, Krey T, Bošnjak B, Förster R, Behrens GMN. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021 Jul 14. doi: 10.1038/s41591-021-01449-9. Epub ahead of print. PMID: 34262158.
7. Since Media Center. Expert reaction to preprint on immune response to mixed dose scheduling of COVID vaccines from the Com-COV study [Internet]. 2021 June 28th. Accessed on August 28th, 2021. Available from: expert reaction to preprint on immune response to mixed dose scheduling of COVID vaccines from the Com-COV study | Science Media Centre.
8. Makszimov V,. Tests show lack of antibodies for those vaccinated with China’s jab (2021) [Internet]. EURACTIV.com with Telex. Accessed on August 27th, 2021. Available from: https://www.euractiv.com/section/politics/short_news/tests-show-lack-of-antibodies-for-those-vaccinated-with-chinas-jab/.
9. Ferenci T, Sarkadi B. Virus neutralizing antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine. medRxiv. 2021 July 29. doi: https://doi.org/10.1101/2021.07.15.21260362.
10. Fermin M,. Ban on travelers vaccinated with Sinovac, Sinopharm probed (May 25th, 2021) [Internet]. Accessed on August 27th, 2021. Available from: Ban on travelers vaccinated with Sinovac, Sinopharm probed | Philippines Lifestyle News.
11. Mahase E. Covid-19: Moderna and Novavax vaccines to be tested in mixing vaccines trial BMJ 2021; 373 :n971 doi:10.1136/bmj.n971.
12. Callaway E. Mix-and-match COVID vaccines trigger potent immune response [Internet]. Nature. 2021 May 19th. Accessed on August 27th, 2021. Available from: Mix-and-match COVID vaccines trigger potent immune response (nature.com).
13. Duarte-Salles, T., & Prieto-Alhambra, D. (2021). Heterologous vaccine regimens against COVID-19. Lancet (London, England), 398(10295), 94–95. https://doi.org/10.1016/S0140-6736(21)01442-2.
14. Deming, M.E., Lyke, K.E. A ‘mix and match’ approach to SARS-CoV-2 vaccination. Nat Med (2021). https://doi.org/10.1038/s41591-021-01463-x.
15. Liu, X., Shaw, R. H., Stuart, A., Greenland, M., Aley, P. K., Andrews, N. J., Cameron, J. C., Charlton, S., Clutterbuck, E. A., Collins, A. M., Dinesh, T., England, A., Faust, S. N., Ferreira, D. M., Finn, A., Green, C. A., Hallis, B., Heath, P. T., Hill, H., Lambe, T., … Com-COV Study Group (2021). Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet (London, England), S0140-6736(21)01694-9. Advance online publication. https://doi.org/10.1016/S0140-6736(21)01694-9.
16. Behrens, G. M., Cossmann, A., Stankov, M. V., Nehlmeier, I., Kempf, A., Hoffmann, M., & Pöhlmann, S. (2021). SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination. Lancet (London, England), S0140-6736(21)01891-2. Advance online publication. https://doi.org/10.1016/S0140-6736(21)01891-2.
17. Mohammad, Ameen M. MD The pandemic of coronavirus: misconceptions from the land of Mesopotamia, International Journal of Surgery: Global Health: May 2021 - Volume 4 - Issue 3 - p e52. doi: 10.1097/GH9.0000000000000052
Downloads
Published
2021-12-26
How to Cite
1.
Mohammad AM, Sgery ASH. Heterologous COVID-19 Vaccination; Sinopharm and Pfizer-BioNTech. Iraq Med J [Internet]. 2021 Dec. 26 [cited 2024 Nov. 25];5(4). Available from: https://mail.iraqmedj.org/index.php/imj/article/view/1146
Issue
Section
Short Communications